Our Discoveries

Stock image depicting a CAR T cell (blue) attacking a cancer cell (orange). Image: iStock

T-cell receptors can help CAR T cells steer clear of healthy tissue while they attack tumors

Adding a specific T-cell receptor to CAR T cells may reduce side effects of immunotherapies designed to target solid tumors.

CD45R-stained IHC image depicting B cells within a tertiary lymphoid structure in a triple-treated cholangiocarcinoma tumor

Study uncovers mechanism behind effectiveness of three-drug combination in patients with a rare bile duct cancer

Combining anti-VEGF therapy with immune checkpoint inhibitors stimulated the production of B cells to fight cholangiocarcinoma, a rare bile duct cancer.

Microscopy image of B-cell acute lymphoblastic leukemia

Condition of patients’ immune cells can affect how they respond to immunotherapy

Researchers found that T cells in patients whose cancers did not respond to CD22 CAR T-cell therapy showed markers of cellular exhaustion and were in a later stage of development.

Combination immunotherapy shrank a variety of metastatic solid cancers

Results of a clinical trial led by Steven A. Rosenberg, M.D., Chief and Senior Investigator in the Surgery Branch, showed that a new form of tumor infiltrating lymphocyte (TIL) therapy dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers. The findings, published April 1, 2025, in Nature Medicine, offer hope that this personalized immunotherapy regime could be used to treat a variety of solid tumors, which has so far eluded researchers developing cell-based therapies.

Targeting two proteins leaves some cancer cells vulnerable to chemotherapy

Targeting two proteins that cancer cells rely on to sustain their metabolism and DNA repair capabilities can double the survival rate of mice with lung cancer tumors. Cross referencing with data from The Cancer Genome Atlas of human tumors suggests that these findings could translate to people.

DNA breakage and synthesis in the cell nucleus

Research uncovers a novel mechanism for cells to recover from DNA damage

A newly discovered cellular mechanism sheds light on how cancer cells proliferate despite damage from anti-cancer treatments, providing a target for new therapies.

An illustration of papillomas in the throat

Innovative gene therapy shows promise in treating patients with recurrent respiratory papillomatosis

A clinical trial led by CCR researchers demonstrated the effectiveness of the novel treatment, PRGN-2012, against recurrent respiratory papillomatosis in adults. The results serve as the foundation for an application for accelerated approval to the U.S. Food and Drug Administration (FDA).

Image of the BRCA2 protein with a sliding scale of color indicating the regions containing certain variants. Blue regions contain benign variants, while red regions contain pathogenic regions.

T-cell receptors can help CAR T cells steer clear of healthy tissue while they attack tumors

Study uncovers mechanism behind effectiveness of three-drug combination in patients with a rare bile duct cancer

Condition of patients’ immune cells can affect how they respond to immunotherapy

Combination immunotherapy shrank a variety of metastatic solid cancers

Targeting two proteins leaves some cancer cells vulnerable to chemotherapy

Research uncovers a novel mechanism for cells to recover from DNA damage

Innovative gene therapy shows promise in treating patients with recurrent respiratory papillomatosis

Researchers categorize thousands of BRCA2 mutations as cancerous or benign

Drug shrinks nerve tumors in adults with neurofibromatosis type 1 in a clinical trial

Mutant RAS can shift other proteins’ positions inside cancer cells

Breadcrumb

Our Discoveries